Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years

NCT04436133 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.

NCT NCT04436133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04436133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years
Lead sponsor
National Vaccine and Serum Institute, China
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2020
Completion date
March 1, 2022
Enrollment
480 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv infection, hpv-related cervical carcinoma